Advances in the Development of Therapeutics and Diagnostics for Women’s Health
Join Pharmaceutical & BioScience Society San Francisco Bay and Women in Bio (WIB) San Francisco Bay Area for an online symposium discussing women’s health therapeutics and diagnostics.
Speakers’ Bios
Dr. Julie Andersen is a Professor at the Buck Institute. She has published more than 200 scientific papers and holds several patents on work from her laboratory. Dr. Andersen has been recognized for her research with a Glenn Award and a senior scholarship from the Ellison Medical Foundation. She was elected a fellow of the Society for Free Radicals in Biology and Medicine in 2013. She currently serves as an Editor in Chief of the journal Aging Biology. Dr. Andersen has extensive experience working with both biotech companies and medical foundations.
Laura Esserman, MD, MBA is the director of the UCSF Breast Care Center, and is recognized as a thought leader in cancer screening and over-diagnosis, as well as innovative clinical trial design. She led the creation of the University of California-wide Athena Breast Health Network, a learning system designed to integrate clinical care and research as it follows 150,000 women from screening through treatment and outcomes. The Athena Network launched the PCORI-funded WISDOM Study, which tests a personalized approach to breast cancer screening in 100,000 women. She is also a leader of the innovative I-SPY TRIAL model, designed to accelerate the identification and approval of effective new agents for women with high risk breast cancers.
Meredith Hartley graduated from Dartmouth College earning her AB degree in Chemistry with high honors. She then earned her PhD in Biological Chemistry at Massachusetts Institute of Technology working with Dr. Barbara Imperiali. Following graduate school, Dr. Hartley moved to Oregon Health & Science University (OHSU) in Portland, Oregon as a postdoctoral fellow with Dr. Thomas Scanlan. At OHSU, she validated the use of thyromimetics for treating diseases of myelin damage in preclinical models of multiple sclerosis and an inborn error of metabolism called X-linked adrenoleukodystrophy.
Dr. Hartley joined the University of Kansas as an Assistant Professor in January 2020. Her laboratory investigates the connections between brain lipids, hormones, and myelin with the goal of developing novel therapies for neurological diseases.
Ridhi Tariyal, BS, Georgia Tech; MBA, Harvard University; SM, MIT; Blavatnik Fellow; Ferolyn Fellow, is CEO and co-Founder of NextGen Jane. At NextGen Jane, Ridhi has driven the development of a novel menstrual data platform characterizing uterine biology at a molecular level. In this effort, she has raised capital, established an IP position, and developed a team to create both novel hardware and software to change how women access care. Before NGJ, Ridhi worked at the Broad Institute and at Bristol Myers Squibb.
Hosted by:
